Date: 2014-04-08
Type of information: Nomination
Compound: director
Company: Atara Biotherapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 8, 2014, Atara Biotherapeutics has strengthened its board of directors and executive team by appointing Matthew K. Fust as a director and hiring Mitchall G. Clark, B.Pharm, as chief regulatory and quality assurance officer. Mr. Fust most recently served for five years as executive vice president and chief financial officer of Onyx Pharmaceuticals, where his responsibilities included the corporate finance, accounting, and information technology organizations, along with other operating functions at the company. Prior to Onyx, Fust spent more than five years as senior vice president and chief financial officer of Jazz Pharmaceuticals, and prior to that he was CFO at Perlegen Sciences and ALZA Corporation. Fust currently serves as a board member and audit committee chair at MacroGenics, Sunesis Pharmaceuticals, and Ultragenyx Pharmaceutical.
- Prior to joining Atara, Mr. Clark was senior vice president, regulatory affairs at Los Angeles-based Nantworks Group of Companies where he established the regulatory affairs function. Prior to that he was senior vice president, regulatory affairs at Abraxis where he led the regulatory team responsible for the global regulatory approvals of Abraxane® at Celgene after the Abraxis acquisition. In addition, Clark spent more than 13 years in senior management positions at a number of pharmaceutical companies including American Pharmaceutical Partners. and VivoRX.
Financial terms:
Latest news:
Is general: Yes
